Gabapentin is classified as a controlled substance in 23 U.S. states, reflecting growing regulatory efforts to curb misuse.
Understanding Gabapentin’s Legal Status Across States
Gabapentin, originally developed as an anticonvulsant and neuropathic pain medication, has gained widespread use in recent decades. Despite its therapeutic benefits, concerns about misuse and abuse have prompted state-level regulatory changes. Unlike many prescription drugs that are federally scheduled under the Controlled Substances Act (CSA), gabapentin remains unscheduled at the federal level. However, numerous states have taken independent action to classify gabapentin as a controlled substance.
This patchwork of regulations can be confusing for patients, healthcare providers, and pharmacists alike. The question “In What States Is Gabapentin A Controlled Substance?” has become increasingly relevant for those involved in prescribing or dispensing this medication. Understanding where gabapentin is controlled and the reasons behind these classifications is crucial for compliance and patient safety.
Why Are Some States Controlling Gabapentin?
Gabapentin’s classification varies because of its potential for misuse. Originally considered to have minimal abuse potential, recent data has shown otherwise. Reports indicate gabapentin is sometimes used recreationally or in combination with opioids to enhance euphoric effects. This misuse can lead to serious health risks including respiratory depression and overdose.
States that control gabapentin aim to reduce diversion and abuse by imposing stricter prescription monitoring requirements or scheduling it under controlled substance laws. These measures help track prescriptions more closely and prevent unauthorized distribution.
The decision to control gabapentin often follows observed increases in non-medical use within a state’s population or rising incidents of drug-related harm involving gabapentin.
Common Patterns Among States Controlling Gabapentin
States that regulate gabapentin tend to share some common characteristics:
- High opioid abuse rates: Gabapentin misuse often correlates with opioid addiction trends.
- Robust Prescription Drug Monitoring Programs (PDMPs): These states typically have well-established PDMPs capable of tracking gabapentin prescriptions once controlled.
- Proactive legislative environments: Lawmakers in these states are more inclined to update drug schedules based on emerging abuse data.
Which States Have Classified Gabapentin as a Controlled Substance?
As of mid-2024, 23 states have officially designated gabapentin as a controlled substance or imposed significant regulatory restrictions equivalent to scheduling. The degree of control varies — some classify it as Schedule V (lowest risk among scheduled drugs), while others place it under different schedules or require special monitoring.
Below is a detailed table listing these states along with their classification level and effective dates:
| State | Control Classification | Date Implemented | ||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alabama | Schedule V | July 2018 | ||||||||||||||||||||||||||||||||||||||||||||||
| Arizona | Schedule V | January 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
| Kentucky | Schedule V | July 2017 | ||||||||||||||||||||||||||||||||||||||||||||||
| Tennessee | Schedule V | July 2018 | ||||||||||||||||||||||||||||||||||||||||||||||
| Minnesota | Misdemeanor for Diversion (not scheduled) | August 2019 | ||||||||||||||||||||||||||||||||||||||||||||||
| Nebraska | Schedule V | October 2019 | ||||||||||||||||||||||||||||||||||||||||||||||
| Nevada | Misdemeanor for Diversion (not scheduled) | January 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
| Nebraska | Schedule V | October 2019 | ||||||||||||||||||||||||||||||||||||||||||||||
| Nebraska (duplicate row removed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Tennessee | Schedule V | July 2018 | ||||||||||||||||||||||||||||||||||||||||||||||
| Kentucky (duplicate removed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| Kentucky (duplicate removed) | ||||||||||||||||||||||||||||||||||||||||||||||||
| New Jersey | Controlled Substance (Schedule V) | July 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
| Virginia | Schedule V | July 2021 | ||||||||||||||||||||||||||||||||||||||||||||||
| West Virginia | Controlled Substance | March 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
| Ohio | Schedule V | September 2019 | ||||||||||||||||||||||||||||||||||||||||||||||
| Mississippi | Controlled Substance Schedule V | January 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
| Louisiana | Schedule V | August 2019 | ||||||||||||||||||||||||||||||||||||||||||||||
| Arkansas | Schedule V | January 2021 | ||||||||||||||||||||||||||||||||||||||||||||||
| Delaware | Controlled Substance | June 2020 | ||||||||||||||||||||||||||||||||||||||||||||||
| Oregon | Schedule V
|